My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

58.93 +0.39 (+0.67%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

38 39 Next >

Why IDEAYA Biosciences Shares Plunging Today ↗

August 15, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

August 15, 2022

On Monday, 31 companies hit new 52-week lows.

Via Benzinga

Landmark Drug Pricing Reform Bill Passes Congress House ↗

August 15, 2022

The U.S. House of Representatives voted 220-207 to pass new, wide-ranging legislation allowing Medicare drug price negotiations for the first time and capping seniors’ drug expenses to $2,000 per year...

Via Benzinga

Do I Need to Get A Polio Vaccine? New York Sewer Discovery Triggers Fears About Paralysis-Inducing Virus ↗

August 12, 2022

New York officials have detected polio in the city's wastewater, suggesting the virus has been circulating in the local area.

Via Benzinga

GSK Confirms Rotavirus Vaccine Shortage, Hits Four African Countries: Report ↗

August 10, 2022

Via Benzinga

Vir Biotech Shuns FDA Submission Plans For GSK-Partnered COVID-19 Treatment ↗

August 10, 2022

Via Benzinga

Mersana, GSK Ink $1.36B Biobuck Deal For Cancer-Focused Therapy ↗

August 09, 2022

Via Benzinga

Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke ↗

August 11, 2022

Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

August 11, 2022

On Thursday, 22 companies reached new 52-week lows.

Via Benzinga

GSK, PFE, SNY Stocks Fall on Zantac Litigation ↗

August 11, 2022

You may think safety concerns about Zantac from 2019 are old news now, but GSK stock traders and others are worried about the repercussions.

Via InvestorPlace

Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms ↗

August 11, 2022

These companies are at the center of lawsuits claiming Zantac causes cancer.

Via Investor's Business Daily

Sonos, Bumble And Some Other Big Stocks Moving Lower In Today's Pre-Market Session ↗

August 11, 2022

Via Benzinga

Drug Behemoth GSK Delivers Strong Beat And Raise, But Shares Fell ↗

July 27, 2022

The company expects full-year sales to grow 6%-8% and for earnings to rise 1%.

Via Investor's Business Daily

New GSK Q2 Highlights: Shingles Vaccine Back In Demand, Antibiotics Recover, Forecast Boost ↗

July 27, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

August 10, 2022

During Wednesday, 52 stocks hit new 52-week lows.

Via Benzinga

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful ↗

August 09, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Dividend Income Update July 2022 ↗

August 09, 2022

The start of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. Let’s take a look back at...

Via Talk Markets

Biotech Investors: August's Key PDUFA Catalysts You Must Know ↗

July 31, 2022

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...

Via Benzinga

Recap Of Friday's Biotech Catalysts - End of The Day Summary ↗

July 29, 2022

Via Benzinga

Stock Market Rally Powers Higher On Fed Rate Hints; Apple, Microsoft, Meta, Amazon, Google Key Earnings: Weekly Review ↗

July 29, 2022

The major indexes made big moves amid key earnings and another big Fed rate hike.

Via Investor's Business Daily

Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗

July 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary ↗

July 27, 2022

Via Benzinga

IDEAYA's Cancer Candidate Shows Early Tumor Modulation ↗

July 27, 2022

Via Benzinga

The 3 Best Market Sectors for the Second Half of 2022 ↗

July 27, 2022

Compelling themes will drive a recovery in some sectors over the second half of 2022. The following are the best market sectors to buy into.

Via InvestorPlace

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy ↗

July 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Jim Cramer Says This Stock Costs About $3, But 'If You Wait Long Enough' You Can Buy It For $2 ↗

July 27, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Blackstone Inc. (NYSE: BX) over Apollo Global Management Inc (NYSE: APO).

Via Benzinga

Benzinga Before The Bell: Twitter Shareholder Proposal Date Set, T-Mobile's Strong FY22 Outlook, Shopify's Job Cuts And Other Top Financial Stories Wednesday, July 27 ↗

July 27, 2022

Reuters Monkeypox Emergency Could Last Months, According To Experts

Via Benzinga

7 Dividend Stocks to Buy on the Dip ↗

July 27, 2022

The stock market is volatile and bottoming, making it a good time to buy dividend stocks on the dip. Here are seven worth your consideration.

Via InvestorPlace

This Analyst Says GSK Spin-Off Haleon Offers "Best Of Both Consumer Worlds" ↗

July 22, 2022

Citi group has initiated coverage on GSK plc's (NYSE: GSK) consumer healthcare spin-off Haleon Plc (NYSE: HLN) with a Buy rating and a price target of 360p.

Via Benzinga

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.